Current Trends in Nucleic Acids

References

[1] Alameh MG, Tombacz I, Bettini E (2021). Vaccines by inducing robust T follicular helper cell and humoral responses. Journal of Immunity, 54: 2877 – 2892.

[2] Allen TM, Cullis PR (2013). Lipid nanoparticles enhance the efficacy of mRNA and protein subunit Liposomal drug delivery systems: from concept to clinical applications. Advanced Drug Delivery Review, 65(1): 36–48.

[3] Anzalone, A.V., Randolph, P.B., Davis, J.R., Sousa, A.A., Koblan, L.W., & Levy, J.M. (2019). Asymptomatic infections. Journal of Infectious Disease, 226: 920 – 927.

[4] Babaei, M., Eshghi, H., Abnous, K., Rahimizadeh, M., & Ramezani, M. (2017). Promising gene delivery system based on polyethylenimine- modified silica nanoparticles. Journal of Cancer Gene and Therapeutics, 24(4): 156 – 164.

[5] Bahl, K., Senn, J.J., & Yuzhakov, O. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Journal of Molecular Therapy, 25: 1316–1327.

[6] Burdett, T., & Nuseibeh, S. (2023). Changing trends in the development of AAV-based gene therapies: a meta-analysis of past and present therapies. Gene Therapeutics, 30(4): 323–335.

[7] Chen, J., Chen, J., & Xu, Q. (2022). Current developments and challenges of mRNA vaccines. Annual Review of Biomedical Engineering, 24: 85–109.

[8] Cerritelli, S.M., & Crouch, R.J. (2009). Ribonucleases H: the enzymes in eukaryotes. Journal of Federation of European Biochemical Societies, 276: 1494 – 1505.

[9] Damase, T.R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R.I., & Cooke, J.P. (2021). The Limitless Future of RNA Therapeutics. Journal of Frontier in Bioengineering and Biotechnology, 9: 628 – 637.

[10] Danhier, F. (2016). To exploit the tumour microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? Journal Control Release, 244: 108–121.

[11] Davis, R. (2022). Nucleic acid testing applications in molecular diagnostics. Journal of Industrial Biotechnology, 6(4): 120.

[12] Dias, N., Dheur, S., Nielsen, P.E., Gryaznov, S., Van Aerschot, A., Herdewijn, P., Helene, C., & Saison-Behmoaras, T.E. (1999). Antisense PNA tridecamers targeted region of Haras mRNA arrest polypeptide chain elongation. Journal of Molecular Biology, 294: 403 – 416.

[13] Elbashir, S.M., Hrborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001). Duplexes of 21 – nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature Review, 411: 494 – 498.

[14] Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B.R., & Strahs, A. (2017). A highly durable RNAi therapeutic inhibitor of PCSK9. National England Journal of Medicine, 376(1): 41–51.

[15] Geisbert, T.W., Lee, A.C.H., & Robbins, M. (2010). Post exposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet, 375: 1896–1905.

[16] Hannay, E., & Sands, P. (2021). One year into the Covid-19 pandemic, testing is as vital as ever. Available at: https://www.telegraph.co.uk/global-health/science-and-disease/ one-year-covid-19-pandemic-testing-vital-ever/.

[17] Hasell, J., Mathieu, E., & Beltekian, D. (2020). A cross-country database of COVID-19 testing. Journal of Science Data, 7: 345.

[18] Hayashi, C.T.H., Cao, Y., & Clark, L.C. (2022). mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. Nature Partner Journal of Vaccines, 7: 155.

[19] Hoffman, S.L., Vekemans, J., Richie, T.L., Duffy, P.E. (2015). The march toward malaria vaccines. America Journal of Medicine, 49 (4): 319–333.

[20] Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.J. (2020). Therapeutic siRNA: State of the art signal transduction. Journal of Targeted Therapy, 5: 101.

[21] Iuliano, A.D., Roguski, K.M., & Chang, H.H. (2018). Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet, 391: 1285–1300.

[22] Jackson, N.A.C., Kester, K.E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020). The promise of mRNA vaccines: a biotech and industrial perspective. Journal of Nature Partner, 5: 11.

[23] Jagger, B.W., Dowd, K.A., & Chen, R.E. (2019). Protective efficacy of nucleic acid vaccines against transmission of Zika virus during pregnancy in mice. Journal of Infectious Disease, 220: 1577–1588.

[24] Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. Jirikowski G.F., Sanna, P.P., Maciejewski-Lenoir, D., & Bloom, F.E. (1992). Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. Journal of Science, 255: 996–998.

[25] Kariko, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Journal of Immunity, 23: 165–175.

[26] Kristen, A.V., Ajroud-Driss, S., Conceicao, I., Gorevic, P., kyriakides, T., & Obici, L.P. (2019). An RNAi therapeutic for te treatment of hereditary transthyretin-mediated Amyloidosis. Journal of Disease Management, 9: 5 – 23.

[27] Labatut, A.E., & Mattheolabakis, G. (2018). Non-viral based miR delivery and recent developments. European Journal of Pharmacology and Biopharmacology, 128: 82–90.

[28] Larsen, S.E., Baldwin, S.L., & Coler, R.N. (2023). Tuberculosis vaccines update: is an RNA-based vaccine feasible for tuberculosis? International Journal of Infectious Diseases, 130 (1): 47–51.

[29] Lee, K., Kim, M., Seo, Y., & Lee, H. (2018). Development of mRNA vaccines and their prophylactic and therapeutic applications. Journal of Nano Resource, 11: 5173 – 5192.

[30] Lee, S.H., Park, S.M., & Kim, B.N. (2019). Emerging ultrafast nucleic acid amplification technologies for next generation molecular diagnostics. Journal of Biosenseor and Bioelectron, 141: 111 – 148.

[31] Lewnard, J.A., & Cobey, S. (2018). Immune history and influenza vaccine effectiveness. Journal of Vaccines, 6: 28.

[32] Liang, X. H., Sun, H., Nichols, J.G., & Crooke, S.T. (2017). RNase H1 – Dependent Antisense Oligonucleotides are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Journal of Molecular Therapy, 25: 2075 – 2092.

[33] Lindgren, G., Ols, S., & Liang, F. (2017). Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Frontier of Immunology, 8: 1539.

[34] Lujan, H., Griffin, W.C., Taube, J.H., & Sayes, C.M. (2019). Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells. International Journal of Nanomedicine, 14: 5159–5173.

[35] Manikandan, C., Kaushik, A., & Sen, D. (2020). Viral vector: potential therapeutic for glioblastoma multiforme. Cancer Gene Therapeutics, 27(5): 270–279.

[36] Martinez, D.R., Schafer, A., & Leist, S.R. (2021). Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Journal of Science, 373: 991–998.

[37] Montefiori, D.C., Roederer, M., Morris, L., & Seaman, M.S. (2018). Neutralization tiers of HIV-1. Curriculum Opined on HIV AIDS, 13: 128–136.

[38] Mu, Z., Haynes, B.F., & Cain, D.W. (2021). HIV mRNA vaccines-progress and future paths. Journal of Vaccines, 9: 134.

[39] Mu, Z., Wiehe, K., & Saunders, K.O. (2022). mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Journal of Cell Replication, 38: 110514.

[40] Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2025). Nucleic Acid therapeutics: past, present, and future. Journal of Molecular Therapy, 36: 1 -25.

[41] Nambiar, T.S., Baudrier, L., Billon, P., & Ciccia, A. (2022). CRISPR-based genome editing through the lens of DNA repair. Journal of Molecular Cell, 82: 348 – 388.

[42] Ondoa, P., Kebede, Y., & Massinga, M. (2020). COVID-19 testing in Africa: lessons learnt. Lancet Microbe, 1:103–104.

[43] Pacesa, M., Pelea, O., & Jinek, M. (2024). Past, present, and future of CRISPR genome editing technologies. Journal of Cell, 187: 1076 – 1100.

[44] Pardi, N., Hogan, M.J., & Pelc, R.S. (2017). Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Journal of Nature, 543: 248–251.

[45] Pattnaik, A., Sahoo, B.R., & Pattnaik, A.K. (2020). Current status of Zika virus vaccines: successes and challenges. Journal of Vaccines, 8: 266.

[46] Raguram, A., Banskota, S., & Liu, D.R. (2022). Therapeutic in vivo delivery of gene editing agents. Journal of Cell, 185: 2806 – 2827.

[47] Raj, D.K., Das Mohapatra, A., & Jnawali, A. (2020). Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria. Journal of Nature, 582: 104–108.

[48] Richner, J.M, Himansu, S., & Dowd, K.A. (2017). Modified mRNA vaccines protect against Zika virus infection. Journal of Cell, 168: 1114–1125.

[49] Rinaldi, C., & Wood, M.J.A. (2018). Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nature Review, 14: 9 – 21.

[50] Rurik, J.G., Tombacz, I., & Yadegari, A. (2022). CAR T cells produced in vivo to treat cardiac injury. Journal of Science, 375: 91–99.

[51] Sato, Y., Sakurai, Y., Kajimoto, K., Nakamura, T., Yamada, Y., Akita H (2017). Innovative technologies in nanomedicines: from passive targeting to active targeting/from controlled pharmacokinetics to controlled intracellular pharmacokinetics. Macromolecule Bioscience, 17(1): 1600179.

[52] Saunders KO, Pardi N, Parks R (2021). Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in zika virus. Nature Review, 5: 105 – 112.

[53] Schnee, M., Vogel, A.B., & Voss, D. (2016). An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. Public Library of Science, 10: 4746.

[54] Schrager, L.K., Vekemens, J., Drager, N., Lewinsohn, D.M., & Olesen, O.F. (2020). The status of tuberculosis vaccine development. Lancet Infectious Diseases, 20: 28–37.

[55] Sung YK, Kim SW (2019). Recent advances in the development of gene delivery systems. Biomaterial Resource, 23: 8.

[56] Waghela, I.N., Mallory, K.L., & Taylor J.A. (2022). Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS. Frontier of Immunology, 13: 1026052.

[57] Wang, Q., Liang, Q., Dou, J., Zhou, H., Zeng, C., & Pan, H. (2023). Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nature Nanotechnology, 19: 95.

[58] Wang, Y., Bruggeman, K.F, Franks, S., Gautam, V., Hodgetts, S.I., Harvey, A.R. (2022). Is viral vector gene delivery more effective using biomaterials? 10(1): 1238.

[59] Wang, P., He, D., Li, Y., Wang, W., & Luo, X. (2019). Eliminating mcr-1-harbouring plasmids in clinical isolates using the CRISPR/cas 9 system. Journal of Antimicrobiology and Chemotherapy, 74: 2559 – 2565.

[60] Whiley, D.M., Tapsall, J.W., & Sloots, T.P. (2006). Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. Journal of Molecular Diagnostics, 8(1): 1 – 15.

[61] Wittrup, A., & Lieberman, J. (2015). Knocking down disease: a progress report on siRNA therapeutics. Journal of Nature Review and Genetics, 16: 543 – 55

[62] Wu Y, Tang Y, Xie S, Zheng X, Zhang S, Mao J (2020). Chimeric peptide supramolecular nanoparticles for plectin-1targeted miRNA-9 delivery in pancreatic cancer. 10(3): 1151–1165.

[63] Xiong, Q., Lee, G.Y., Ding, J., Li, W., Shi J (2018). Biomedical applications of mRNA nanomedicine. Nanomedicine Resource, 11(10): 5281–5309.

[64] Xue T, Stavropoulos E, Yang M (2004). RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Journal of Infectious Immunology, 72: 6324–6329.

[65] Young LS, Searle PF, Onion D, Mautner V (2006). Viral gene therapy strategies: from basic science to clinical application. Journal of Pathology, 208(2): 299–318.

[66] Zhang C, Maruggi G, Shan H, Li J ( 2019). Advances in mRNA vaccines for infectious diseases. Frontier of Immunology, 10: 594.

[67] Zhang L, Liao Y, Tang L (2019). MicroRNA-34 family: a potential tumour suppressor and therapeutic candidate in cancer. Journal of Experimental Clinical Cancer Resource, 38(1): 1170.

@article{1710336,
      author = {Okereke, Chibueze Aphogu, Prof. Ufelle Silas},
      title = {Current Trends in Nucleic Acids},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {9},
      number = {2},
      pages = {1052-1063},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1710336.pdf},
      abstract = {Recent advancements in nucleic acid research have revolutionized our understanding of genetic regulation, diagnostics, and therapeutics. The emergence of next-generation RNA technologies, including RNA-based vaccines and RNA editing tools such as Adenosine Deaminase Acting on RNA (ADAR)-mediated systems, has expanded the utility of nucleic acids beyond traditional gene expression roles. In parallel, Clustered Regularly Interspaced Short Palindomic Repeats (CRISPR)-Cas systems have evolved into more precise, efficient, and programmable platforms for genome and epigenome editing, with innovations like CRISPR-Cas9 enabling nucleic acid detection and RNA manipulation. Moreover, nanopore sequencing and single-molecule real-time sequencing technologies are driving ultra-fast, high-resolution genomic analysis, empowering personalized medicine and microbiome profiling. Collectively, these trends mark a transformative era in nucleic acid research, fostering breakthroughs in precision medicine, synthetic biology, and disease diagnostics. },
      keywords = {Nucleic acid, Deoxyribonucleic acid, Ribonucleic acid, Therapeutics, Diagnostics, Gene editing, Vaccine, Vectors, Nanoparticles. },
      month = {August},
  }